News | August 07, 2024
Sucralose safe to use in small doses; reveals MDRF study
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
